1. Protein Tyrosine Kinase/RTK
  2. Btk

Btk

Bruton's tyrosine kinase (BTK) also known as tyrosine-protein kinase BTK is an enzyme that in humans is encoded by the BTK gene. BTK is a kinase that plays a crucial role in B-cell development. Its exact mechanism of action remains unknown, but it plays a crucial role in B cell maturation as well as mast cell activation through the high-affinity IgE receptor. Btk contains a PH domain that binds phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3 binding induces Btk to phosphorylate phospholipase C, which in turn hydrolyzes PIP2, a phosphatidylinositol, into two second messengers, inositol triphosphate (IP3) and diacylglycerol (DAG), which then go on to modulate the activity of downstream proteins during B-cell signalling.

Btk Related Products (26):

Cat. No. Product Name Effect Purity
  • HY-10997
    PCI-32765 Inhibitor 99.87%
    PCI-32765 is a selective, irreversible Btk inhibitor with IC50 value of 0.5 nM.
  • HY-17600
    Acalabrutinib Inhibitor 98.74%
    Acalabrutinib (ACP-196) is a second-generation, selective, irreversible inhibitor of BTK (Bruton's tyrosine kinase) that has improved pharmacologic features, including favorable plasma exposure, rapid oral absorption, a short half-life, and the absence of irreversible targeting to alternative kinases, such as EGFR,TEC, and ITK.
  • HY-18012
    AVL-292 Inhibitor 99.95%
    AVL-292 is a covalent, highly selective, orally active small molecule inhibitor of Btk with IC50 value of 0.5 nM; >1400-fold selectivity over the other kinases assayed.
  • HY-19834
    GDC-0853 Inhibitor 99.42%
    GDC-0853 is a potent and orally BTK inhibitor.
  • HY-15427
    GDC-0834 Inhibitor 98.02%
    GDC-0834 is a potent and selective BTK inhibitor.
  • HY-101474
    BGB-3111 Inhibitor 99.70%
    BGB-3111 is a potent, selective and orally available Bruton's tyrosine kinase (Btk) inhibitor.
  • HY-101215
    Evobrutinib Inhibitor 98.17%
    Evobrutinib is an inhibitor of Bruton's tyrosin kinase (Btk) inhibitor extracted from patent US20140162983 example 0174.
  • HY-80002
    BMX-IN-1 Inhibitor
    BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX) that targets Cys496 in the BMX ATP binding domain with IC50 of 8 nM, also targets the related Bruton’s tyrosine kinase (BTK) with an IC50 value of 10.4 nM, but is more than 47-656-fold less potent against Blk, JAK3, EGFR, Itk, or Tec activity.
  • HY-15771
    ONO-4059 Inhibitor 98.31%
    ONO-4059 is a highly selective, orally bioavailable BTK inhibitor with a potency (IC50) of 2.2 nM.
  • HY-18009
    LFM-A13 Inhibitor 99.47%
    LFM-A13 is a potent and selective inhibitor of Btk with IC50 of 17.2 uM; also inhibits PLK3 with IC50 of 7.2 uM.
  • HY-18951
    ONO-4059 analog Inhibitor
    The product is the analog of ONO-4059, ONO-4059 is a highly potent and selective Btk inhibitor with an IC50 in the sub-nM range.
  • HY-18018
    RN486 Inhibitor
    RN486 is a selective Btk inhibitor with an IC50 Value of 4.0 nM.
  • HY-11999
    CGI-1746 Inhibitor
    CGI-1746 is a small-molecule Bruton's tyrosine kinase (Btk) inhibitor.
  • HY-15427A
    GDC-0834 Racemate
    GDC-0834 Racemate is the racemate form of GDC-0834, which is a potent and selective BTK inhibitor with in vitro IC50s of 5.9 and 6.4 nM in biochemical and cellular assays, respectively.
  • HY-18010
    PCI 29732 Inhibitor
    PCI 29732 is a selective and irreversible Btk inhibitor with IC50 of 8.2 nM in a FRET based biochemical enzymology assay.
  • HY-80003
    QL47 Inhibitor
    QL47 is a potent, selective and irreversible BTK kinase inhibitor with IC50 of 7 nM.
  • HY-10997A
    PCI-32765 Racemate Inhibitor
    PCI-32765 Racemate is the racemate of PCI-32765.
  • HY-15771A
    ONO-4059 hydrochloride Inhibitor 98.74%
    ONO-4059 is a selective and novel inhibitor of BTK with IC50 2.2 nm, ONO-4059 binds to BTK within B cells, thereby preventing B-cell receptor signaling and impeding B-cell development.
  • HY-13943
    CNX-774 Inhibitor 99.74%
    CNX-774 is a potent, selective, and orally available small molecule inhibitor of Btk (IC50< 1 nM) that forms a ligand-directed covalent bond with Cys-481, a non-conserved amino acid within the active site of the enzyme.
  • HY-15427B
    GDC-0834 S-enantiomer
    GDC-0834 S-enantiomer is the S-enantiomer of GDC-0834.